Soleno Therapeutics, Inc. (SLNO)
- Previous Close
44.99 - Open
45.17 - Bid 42.73 x 100
- Ask 42.87 x 100
- Day's Range
42.21 - 45.17 - 52 Week Range
3.69 - 53.82 - Volume
429,620 - Avg. Volume
418,690 - Market Cap (intraday)
1.578B - Beta (5Y Monthly) -1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-2.36 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
67.00
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
soleno.lifeRecent News: SLNO
Performance Overview: SLNO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLNO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLNO
Valuation Measures
Market Cap
1.58B
Enterprise Value
1.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.33%
Return on Equity (ttm)
-46.45%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-38.99M
Diluted EPS (ttm)
-2.36
Balance Sheet and Cash Flow
Total Cash (mrq)
169.68M
Total Debt/Equity (mrq)
0.26%
Levered Free Cash Flow (ttm)
-12.82M
Research Analysis: SLNO
Company Insights: SLNO
SLNO does not have Company Insights